ICCC 株価分析 — Immucell Corporation (Healthcare >> Biotechnology)
ICCC に関するよくある質問
ICCCのPER(株価収益率)は?
Immucell Corporation(ICCC)は現在PER 40.95倍で取引されています。
ICCCのROE(自己資本利益率)は?
Immucell CorporationのROEは-1.87%です。
ICCCの配当利回りは?
Immucell Corporationの配当利回りは0.00%です。
ICCCの品質スコア(Quality Score)は?
当社のAIはICCCの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ICCCは今が買い時ですか?
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ICCCはどのセクターに属しますか?
Immucell CorporationはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
ICCC AI Analysis Summary
Our AI summary for ICCC: Immucell Corporation (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 40.95, ROE of -1.87%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 11.21
Price
0.15
(1.36%)
Day Change
|
|
|---|
ICCC, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 11.21 |
| PBV / Sector |
3.43 / 5.20
|
| Earning Per Share | -0.06 |
| PE / Sector |
40.95 / 19.97
|
| PEG or PE/Growth / Sector |
11.67 / 1.22
|
| Average 1M Daily Value |
0.31 M
GREAT
|
| Average 1W Daily Value |
0.19 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:59 |
| Symbol | ICCC |
| Name | IMMUCELL CORPORATION |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 9.05 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 100.06 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 56 Evergreen Drive, Portland, ME, United States, 04103
Phone: 207 878 2770
Website: https://immucell.com
Employees: 73
Sector: Healthcare >> Biotechnology
Description: ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google